Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck
Multicentric prospective model-based de-escalation of the elective clinical target volumes (CTV) in radiotherapy of oropharyngeal carcinoma of all stages with the goal to reduce toxicity. The study investigates the feasibility of this approach as measured by the number of expected out-of-field recurrencies based on the
| Condition(s) | Oropharynx Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | Multicentric prospective model-based de-escalation of the elective clinical target volumes (CTV) in radiotherapy of oropharyngeal carcinoma of all stages with the goal to reduce toxicity. The study investigates the feasibility of this approach as measured by the number of expected out-of-field recurrencies based on the individual patient's state of disease progression and risk factors |
| Who can participate | Inclusion Criteria: * Patients with a newly diagnosed (no pre-treatment) squamous cell carcinoma of the oropharynx (i.e. tonsils, base of tongue, oropharyngeal walls, oropharyngeal surface of epiglottis; ICD-10 codes C01, C09, C10), T1-4, N0-3. * Treatment with definitive (chemo) radiotherapy planned, with elective irradiation of the lymph nodes. * Age ≥ 18 years, no upper age limit. * ECOG performance score \< 3. * History/physical examination within 30 days prior to study inclusion by head and neck surgeon and/or radiation oncologist. * FDG-PET scan prior to study inclusion. In case of inability to perform or contra-indication, at least contrast enhanced MRI scan obligatory. * Participants need to provide informed consent. Exclusion Criteria: Inclusion Criteria: * Patients with a newly d |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of Zurich |
| Locations | Zurich, Canton of Zurich, Switzerland; Aarau, Switzerland; Bellinzona, Switzerland; Bern, Switzerland; Geneva, Switzerland; Neuchâtel, Switzerland |
| Start date | 2025-02-04 |
| NCT ID | NCT06563362 |
| Official listing | https://clinicaltrials.gov/study/NCT06563362 |